Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01803269 · ClinicalTrials.gov registry record · Phase 2
Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer
A Phase 2 study, sponsored by University of Chicago.
- Terminated
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT01803269 is a Phase 2 study that was terminated before completion, run by University of Chicago. The registered enrollment target is 29 participants.
The verdict
NCT01803269, a Phase 2 study, was terminated before completion, sponsored by University of Chicago.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
This randomized phase II trial studies how well giving topotecan hydrochloride or cyclodextrin-based polymer-camptothecin CRLX101 works in treating patients with recurrent small cell lung cancer. Drugs used in chemotherapy, such as topotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cyclodextrin-based polymer-camptothecin CRLX101 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet know whether topotecan hydrochloride is more effective than cyclodextrin-based polymer-camptothecin CRLX101 in treating patients with lung cancer.
Interventions
- DRUG topotecan hydrochloride
- DRUG cyclodextrin-based polymer-camptothecin CRLX101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2013-01-16 |
| Est. Completion | 2016-03-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01803269
The ClinicalTrials.gov registry entry for NCT01803269 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which topotecan hydrochloride is the first listed.
NCT01803269 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01803269 about?
NCT01803269 is a clinical study titled "Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer". This randomized phase II trial studies how well giving topotecan hydrochloride or cyclodextrin-based polymer-camptothecin CRLX101 works in treating patients with recurrent small cell lung cancer. Drugs used in chemotherapy, such as topotecan hydrochloride, work in different ways to stop the growth o...
What is the current status of trial NCT01803269?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2013-01-16. Estimated completion is 2016-03-30.
What interventions are being tested in trial NCT01803269?
The interventions under investigation include: topotecan hydrochloride (DRUG), cyclodextrin-based polymer-camptothecin CRLX101 (DRUG).
Who is sponsoring clinical trial NCT01803269?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.